Cargando…

Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors

BACKGROUND: Although checkpoint-based immunotherapy has shown exciting results in the treatment of tumors, around 70% of patients have experienced unresponsiveness. PVRIG is a recently identified immune checkpoint receptor and blockade of which could reverse T cell exhaustion to treat murine tumor;...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yangyang, Zhang, Yu, Cao, Guoshuai, Zheng, Xiaodong, Sun, Cheng, Wei, Haiming, Tian, Zhigang, Xiao, Weihua, Sun, Rui, Sun, Haoyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236157/ https://www.ncbi.nlm.nih.gov/pubmed/34174928 http://dx.doi.org/10.1186/s13045-021-01112-3

Ejemplares similares

All‐trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down‐regulating B7‐H6 expression via c‐Myc signaling
por: Cao, Guoshuai, et al.
Publicado: (2021)

Low-dose immunogenic chemotherapeutics promotes immune checkpoint blockade in microsatellite stability colon cancer
por: Fang, Yuhang, et al.
Publicado: (2022)

PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia
por: Li, Jessica, et al.
Publicado: (2020)

Development of Murine Hepatic NK Cells during Ontogeny: Comparison with Spleen NK Cells
por: Wu, Xian, et al.
Publicado: (2012)

Inhibiting the inhibitors: Checkpoints blockade in solid tumors
por: Mavilio, Domenico, et al.
Publicado: (2013)

CRACC-CRACC Interaction between Kupffer and NK Cells Contributes to Poly I:C/D-GalN Induced Hepatitis
por: Li, Yangxi, et al.
Publicado: (2013)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
por: Sanchez-Correa, Beatriz, et al.
Publicado: (2019)

Modulation of intrinsic inhibitory checkpoints using nano‐carriers to unleash NK cell activity
por: Biber, Guy, et al.
Publicado: (2021)

The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy
por: Sun, Haoyu, et al.
Publicado: (2019)

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
por: André, Pascale, et al.
Publicado: (2018)

Murine models to study human NK cells in human solid tumors
por: Parodi, Monica, et al.
Publicado: (2023)

Nanomaterials-based precision sonodynamic therapy enhancing immune checkpoint blockade: A promising strategy targeting solid tumor
por: Dai, Xinlun, et al.
Publicado: (2023)

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
por: Miao, Diana, et al.
Publicado: (2018)

Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition
por: Zhao, Manzhi, et al.
Publicado: (2023)

PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma
por: Birnbaum, David Jeremie, et al.
Publicado: (2023)

The Emerging Role of NK Cells in Immune Checkpoint Blockade
por: Martinez-Perez, Alejandra, et al.
Publicado: (2022)

Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
por: Cheng, Ying, et al.
Publicado: (2020)

LIGHTing tumor up for checkpoint blockade
por: Liang, Yong, et al.
Publicado: (2016)

Unleashing the power of NK cells in anticancer immunotherapy
por: Vogler, Meike, et al.
Publicado: (2021)

Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies
por: Yang, Richard K., et al.
Publicado: (2020)

Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade
por: Wang, Chensu, et al.
Publicado: (2021)

Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy
por: Grottoli, Melania, et al.
Publicado: (2022)

Checkpoint TIPE2 Limits the Helper Functions of NK Cells in Supporting Antitumor CD8(+) T Cells
por: Bi, Jiacheng, et al.
Publicado: (2023)

Predictive biomarkers for tumor immune checkpoint blockade
por: Tong, Mengting, et al.
Publicado: (2018)

Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200
por: Gorczynski, Reginald M, et al.
Publicado: (2017)

Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice
por: Pieper, Alexander A, et al.
Publicado: (2021)

Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors
por: Wu, Qiuyu, et al.
Publicado: (2023)

Editorial: Targeting metabolism to activate T cells and enhance the efficacy of checkpoint blockade immunotherapy in solid tumors
por: Xia, Zhijia, et al.
Publicado: (2023)

PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models
por: Mitchell, Leah A., et al.
Publicado: (2019)

Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
por: Melaiu, Ombretta, et al.
Publicado: (2020)

How to unleash mitochondrial apoptotic blockades to kill cancers?
por: Deng, Jing
Publicado: (2017)

CAR-NK Cells in the Treatment of Solid Tumors
por: Wrona, Ewa, et al.
Publicado: (2021)

Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
por: Yang, Kangdi, et al.
Publicado: (2023)

NK Cell Dysfunction and Checkpoint Immunotherapy
por: Bi, Jiacheng, et al.
Publicado: (2019)

Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent anti-tumor immunity in melanoma
por: Jacquelot, Nicolas, et al.
Publicado: (2021)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

The Adverse Impact of Tumor Microenvironment on NK-Cell
por: Hu, Ziming, et al.
Publicado: (2021)

Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors
por: Rahmy, Sharif, et al.
Publicado: (2022)

Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager
por: Xiao, Xinghui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c5snkib9klna5faqajqiuknmv0